{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:13:06Z","timestamp":1790014386542,"version":"4.0.1"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T00:00:00Z","timestamp":1674086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82000108, 82070152, 91642111, 81890991"],"award-info":[{"award-number":["82000108, 82070152, 91642111, 81890991"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2018M640884"],"award-info":[{"award-number":["2018M640884"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012245","name":"Science and Technology Planning Project of Guangdong Province","doi-asserted-by":"publisher","award":["2020A1515110310"],"award-info":[{"award-number":["2020A1515110310"]}],"id":[{"id":"10.13039\/501100012245","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004000","name":"Guangzhou Science and Technology Program key projects","doi-asserted-by":"publisher","award":["201803040017"],"award-info":[{"award-number":["201803040017"]}],"id":[{"id":"10.13039\/501100004000","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Immunological phenotypes and differentiation statuses commonly decide the T cell function and anti-tumor ability. However, little is known about these alterations in CML patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>Here, we investigated the immunologic phenotypes (CD38\/CD69\/HLA-DR\/CD28\/CD57\/BTLA\/TIGIT\/PD-1) of T subsets (TN, TCM, TEM, and TEMRA) in peripheral blood (PB) and bone marrow (BM) from de novo CML patients (DN-CML), patients who achieved a molecular response (MR) and those who failed to achieve an MR (TKI-F) after tyrosine kinase inhibitor (TKI) treatment using multicolor flow cytometry.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>CD38 or HLA-DR positive PB CD8+TN and TCM cells decreased in the DN-CML patients and this was further decreased in TKI-F patients. Meanwhile, the level of PD-1 elevated in CD8+ TEM and TEMRA cells from PB in all groups. Among BM sample, the level of HLA-DR+CD8+TCM cells significantly decreased in all groups and CD8+TEMRA cells from TKI-F patients exhibited increased level of TIGIT and CD8+ tissue-residual T cells (TRM)  from DN-CML patients expressed a higher level of PD-1 and TIGIT. Lastly, we found a significantly decreased proportion of CD86+ dendritic cells (DCs) and an imbalanced CD80\/CD86 in the PB and BM of DN-CML patients, which may impair the activation of T cells.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In summary, early differentiated TN and TCM cells from CML patients may remain in an inadequate activation state, particularly for TKI-F patients. And effector T cells (TEM, TEMRA and TRM) may be dysfunctional due to the expression of PD-1 and TIGIT in CML patients. Meanwhile, DCs cells exhibited the impairment of costimulatory molecule expression in DN-CML patients. Those factors may jointly contribute to the immune escape in CML patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1078118","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T07:52:34Z","timestamp":1674114754000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Comprehensive analysis of the immune pattern of T cell subsets in chronic myeloid leukemia before and after TKI treatment"],"prefix":"10.3389","volume":"14","author":[{"given":"Danlin","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianfeng","family":"Zha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangbo","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaohua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyu","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangqiu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/cells10010117","article-title":"Chronic myeloid leukemia: A model disease of the past, present and future","volume":"10","author":"Minciacchi","year":"2021","journal-title":"Cells"},{"key":"B3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40164-020-00185-z","article-title":"Trends in disease burden of chronic myeloid leukemia at the global, regional, and national levels: a population-based epidemiologic study","volume":"9","author":"Ning","year":"2020","journal-title":"Exp Hematol Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13045-021-01077-3","article-title":"Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting","volume":"14","author":"Hou","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202112_27625","article-title":"Tailored tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) based on current evidence","volume":"25","author":"Ciftciler","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B6","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/978-3-319-33198-0_4","article-title":"A review and an update of European LeukemiaNet recommendations for the management of chronic myeloid leukemia","author":"Baccarani","year":"2016","journal-title":"Chronic Myeloid Leuk"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-08-523001","article-title":": Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion","volume":"123","author":"Bachireddy","year":"2014","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13045-021-01055-9","article-title":"Third-line therapy for chronic myeloid leukemia: current status and future directions","volume":"14","author":"Cortes","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.22.012703.104702","article-title":"Central memory and effector memory T cell subsets: function, generation, and maintenance","volume":"22","author":"Sallusto","year":"2004","journal-title":"Annu Rev Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/ni1249","article-title":"Activation of bone marrow-resident memory T cells by circulating, antigen-bearing dendritic cells","volume":"6","author":"Cavanagh","year":"2005","journal-title":"Nat Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2008.11.002","article-title":"Homeostasis of naive and memory T cells","volume":"29","author":"Surh","year":"2008","journal-title":"Immunity"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-018-0001-y","article-title":"The full spectrum of human naive T cells","volume":"18","author":"van den Broek","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40164-022-00291-0","article-title":"TCR engineered T cells for solid tumor immunotherapy","volume":"11","author":"Zhang","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/s41467-019-08871-1","article-title":"Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT","volume":"10","author":"Noviello","year":"2019","journal-title":"Nat Commun"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0078-7","article-title":"Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis","volume":"24","author":"Savas","year":"2018","journal-title":"Nat Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2010.01501.x","article-title":"Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy","volume":"85","author":"Rohon","year":"2010","journal-title":"Eur J Haematol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"137320","DOI":"10.1155\/2010\/137320","article-title":"Changes of immunological profiles in patients with chronic myeloid leukemia in the course of treatment","volume":"2010","author":"Humlova","year":"2010","journal-title":"Clin Dev Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-745992","article-title":"CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors","volume":"129","author":"Hughes","year":"2017","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1080\/10428194.2017.1344905","article-title":"The emerging role of immune checkpoint based approaches in AML and MDS","volume":"59","author":"Boddu","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0175-0","article-title":"Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML","volume":"32","author":"Bruck","year":"2018","journal-title":"Leukemia"},{"key":"B21","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1179\/102453309X385241","article-title":"TCR zeta chain expression in T cells from patients with CML","volume":"14","author":"Chen","year":"2009","journal-title":"Hematology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2000.02415.x","article-title":"Impaired expression of the CD3-zeta chain in peripheral blood T cells of patients with chronic myeloid leukaemia results in an increased susceptibility to apoptosis","volume":"111","author":"Chen","year":"2000","journal-title":"Br J Haematol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2017.03.004","article-title":"The bone marrow microenvironment - home of the leukemic blasts","volume":"31","author":"Shafat","year":"2017","journal-title":"Blood Rev"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-020-0245-2","article-title":"Bone marrow niches in haematological malignancies","volume":"20","author":"Mendez-Ferrer","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061203","article-title":"Immunosuppressive cell subsets and factors in myeloid leukemias","volume":"13","author":"Swatler","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2020.06.081","article-title":"The tumor microenvironment","volume":"30","author":"Anderson","year":"2020","journal-title":"Curr Biol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s40164-022-00296-9","article-title":"Myeloid-derived suppressor cells in hematologic malignancies: two sides of the same coin","volume":"11","author":"Yu","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/nri.2015.3","article-title":"Tissue-resident memory T cells: local specialists in immune defence","volume":"16","author":"Mueller","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201646837","article-title":"CD69: from activation marker to metabolic gatekeeper","volume":"47","author":"Cibrian","year":"2017","journal-title":"Eur J Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.20965","article-title":"Re-balance of memory T cell subsets in peripheral blood from patients with CML after TKI treatment","volume":"8","author":"Yao","year":"2017","journal-title":"Oncotarget"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.160.3.1106","article-title":"Role of CD38 and its ligand in the regulation of MHC-nonrestricted cytotoxic T cells","volume":"160","author":"Cesano","year":"1998","journal-title":"J Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/BF00373317","article-title":"HLA-DR antigens induce proliferation and cytotoxicity of T cells against haptenated (TNP and FITC) self structures","volume":"14","author":"Palacios","year":"1981","journal-title":"Immunogenetics"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18302","article-title":"Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T-cell phenotype","volume":"198","author":"Harrington","year":"2022","journal-title":"Br J Haematol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13407","article-title":"TIGIT as an emerging immune checkpoint","volume":"200","author":"Harjunpaa","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02617-5","article-title":"Differences in PD-1 expression on CD8+ T-cells in chronic myeloid leukemia patients according to disease phase and TKI medication","volume":"69","author":"Lee","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2005.04.011","article-title":"The bone marrow: a nest for migratory memory T cells","volume":"26","author":"Di Rosa","year":"2005","journal-title":"Trends Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0114-2","article-title":"Tissue-resident memory T cells at the center of immunity to solid tumors","volume":"19","author":"Amsen","year":"2018","journal-title":"Nat Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5699(90)90085-N","article-title":"Role of the CD28 receptor in T-cell activation","volume":"11","author":"June","year":"1990","journal-title":"Immunol Today"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF02786473","article-title":"CD28\/CTLA-4 and CD80\/CD86 families: signaling and function","volume":"19","author":"Slavik","year":"1999","journal-title":"Immunol Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2016.02.002","article-title":"Regulating the expression of CD80\/CD86 on dendritic cells to induce immune tolerance after xeno-islet transplantation","volume":"221","author":"Ke","year":"2016","journal-title":"Immunobiology"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-09-179697","article-title":"Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression","volume":"114","author":"Mumprecht","year":"2009","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1078118\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T07:52:38Z","timestamp":1674114758000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1078118\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,19]]},"references-count":43,"alternative-id":["10.3389\/fimmu.2023.1078118"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1078118","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,19]]},"article-number":"1078118"}}